Publications Archive : Page 2 of 20 : The Ott Lab

Discovery of Coronavirus Main Protease Inhibitors with Enhanced Brain Exposure and Potent Oral Efficacy in SARS-CoV-2 and MERS Infection Models

Lizzadro, L., Li, J., Taha, T. Y., Degotte, G., Detomasi, T. C., Zapatero-Belinchon, F. J., Hantz, E. R., Huang, S., Matsui, Y., Henderson, W. R., McCann, J. T., Montano, M., Rosecrans, J., Torres Pomares, D. F., McGovern, B. L., Diaz-Tapia, R., Benjamin, J., Gordon, M. E., Suazo, I. D., Settineri, N. S., … Renslo, A. R. (2026).

Journal of medicinal chemistry, 69(2), 1530–1551. https://doi.org/10.1021/acs.jmedchem.5c03015

Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy In Vivo

Jaishankar, P., Correy, G. J., Matsui, Y., Togo, T., Rachman, M. M., Stevens, M. G. V., Hantz, E. R., Zheng, J., Diolaiti, M. E., Montano, M., Taha, T. Y., Rosecrans, J., Pampel, J., Krogan, N. J., Shoichet, B. K., Ashworth, A., Ott, M., Fraser, J. S., & Renslo, A. R. (2026).

Journal of medicinal chemistry, 69(1), 553–573. https://doi.org/10.1021/acs.jmedchem.5c02933

Author Correction: Transcriptional synergy between Tat and PCAF is dependent on the binding of acetylated Tat to the PCAF bromodomain

Dorr, A., Kiermer, V., Pedal, A., Rackwitz, H. R., Henklein, P., Schubert, U., Zhou, M. M., Verdin, E., & Ott, M. (2026).

The EMBO journal, 45(2), 633–635. https://doi.org/10.1038/s44318-025-00612-z

A non-spike nucleocapsid R204P mutation in SARS-CoV-2 Omicron XEC enhances inflammation and pathogenicity

Tsujino, S., Tsuda, M., Deguchi, S., Ito, J., Taha, T. Y., Nasser, H., Wang, L., Rosecrans, J., Suzuki, R., Suzuki, S., Yoshimatsu, K., Ott, M., Ikeda, T., Sato, K., Takayama, K., Tanaka, S., Tamura, T., Fukuhara, T., & Genotype to Phenotype Japan (G2P-Japan) Consortium (2025).

Nature communications, 17(1), 735. https://doi.org/10.1038/s41467-025-67455-4

Drug-induced phospholipidosis as an artifact in antiviral drug repurposing

Glenn, I. S., Paris, L., White, A. D., Garda, V. G., Montano, M., Khalid, M. M., Kao, A. W., Ott, M., & Shoichet, B. K. (2025).

bioRxiv : the preprint server for biology, 2025.11.20.689520. https://doi.org/10.1101/2025.11.20.689520

The Mac1 ADP-ribosylhydrolase is a therapeutic target for SARS-CoV-2

Suryawanshi, R. K., Jaishankar, P., Correy, G. J., Rachman, M. M., O’Leary, P. C., Taha, T. Y., Matsui, Y., Zapatero-Belinchón, F. J., McCavitt-Malvido, M., Doruk, Y. U., Stevens, M. G. V., Diolaiti, M. E., Jogalekar, M. P., Chen, H., Richards, A. L., Kongpracha, P., Bali, S., Montano, M., Rosecrans, J., Matthay, M., … Fraser, J. S. (2025).

eLife, 14, RP103484. https://doi.org/10.7554/eLife.103484

Meeting Summary for Keystone Symposia on HIV Cure: Antiretroviral Therapy (ART)-Free Control of HIV Infection in Durban, South Africa, 2025

Tanaka, K., Chikowore, T. J. B., Deeks, S. G., Estes, J. D., Ho, Y. C., Jiang, S., Lee, M. J., Li, C., Machinda, A., Martins, M., Mdletshe, P., Ndhlovu, Z. M., Neogi, U., Ott, M. M., Rasmussen, T. A., Reddy, K., Rutishauser, R. L., Farrell-Sherman, A., Tiemessen, C. T., Voss, J. E., … McCune, J. M. (2025).

Pathogens & immunity, 10(2), 196–229. https://doi.org/10.20411/pai.v10i2.885

Discovery of AVI-6451, a Potent and Selective Inhibitor of the SARS-CoV-2 ADP-Ribosylhydrolase Mac1 with Oral Efficacy in vivo

bioRxiv : the preprint server for biology, 2025.10.11.681833. https://doi.org/10.1101/2025.10.11.681833

Public trust in science has declined since COVID – virologists need to unite around safety standards

Ott M, Schwartz O, Sigal A.

646(8083):31-34. doi: 10.1038/d41586-025-03151-z. PMID: 41023166.

HIV-induced T cell quiescence and the origins of viral latency

Li Z, Ott M.

2025 Oct;26(10):1633-1634. doi: 10.1038/s41590-025-02282-9. PMID: 41006602.

Blog

Archives: Publications